How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

585 results for

Free Thyroxine Index

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL

CR by the the international workshop on CLL (iwCLL) and the Lugano Response Criteria for Non-Hodgkin's Lymphoma. duration of response (DOR) [ Time Frame: Up to 3 years ] The interval from the first documentation of confirmed CR or PR (by IRC) to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is CLL progression based on standard criteria excluding lymphocytosis alone. progression free survival (PFS) rate [ Time Frame: From (...) % decrease from baseline in the sum of the products of the greatest perpendicular diameters (SPD) of index lesions. overall survival (OS) rate [ Time Frame: From the start of treatment until the date of death from any cause, whichever comes first, up to 100 months ] The interval from the start of study treatment to death from any cause. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor

2017 Clinical Trials

142. The association of maternal thyroid function with placental hemodynamics. (PubMed)

The association of maternal thyroid function with placental hemodynamics. What is the clinical association of maternal thyroid function with placental hemodynamic function?A higher free thyroxine (FT4) concentration in early pregnancy is associated with higher placental vascular resistance.Suboptimal placental function is associated with preeclampsia (which, in turn, further deteriorates placental hemodynamics and impairs the fetal blood supply), fetal growth restriction and premature delivery (...) . Studies have suggested that thyroid hormone (TH) has a role in placental development through effects on trophoblast proliferation and invasion.This study was embedded in The Generation R cohort, a population-based prospective study from early fetal life onwards in Rotterdam, the Netherlands. In total, 7069 mothers with expected delivery date between April 2002 and January 2006 were enrolled during early pregnancy.Thyroid-stimulating hormone (TSH) and free thyroxine (FT4) concentrations were measured

Full Text available with Trip Pro

2017 Human Reproduction

143. Stimulation of thyroid function by hCG during pregnancy: a risk factor for thyroid disease and a mechanism for known risk factors. (PubMed)

gonadotropin, thyrotropin (TSH), and free thyroxine (FT4) were measured in 5435 pregnant women participating in a prospective cohort. The association of hCG with thyroid disease entities, and the association of known risk factors with thyroidal response to hCG stimulation were studied using multivariable linear regression models.Higher hCG concentrations were associated with a higher risk of subclinical and overt hyperthyroidism. Lower hCG concentrations were associated with a higher risk (...) Stimulation of thyroid function by hCG during pregnancy: a risk factor for thyroid disease and a mechanism for known risk factors. Thyroid autoimmunity is a major risk factor for gestational thyroid disease, and recently various other risk factors have been identified, including maternal age, body mass index (BMI) and parity. Human chorionic gonadotropin (hCG) is an important determinant of gestational thyroid function, yet it is unknown to what extent differences in hCG concentration affect

2017 Thyroid

144. Identifying Subpopulations Vulnerable to the Thyroid-Blocking Effects of Perchlorate and Thiocyanate. (PubMed)

and Nutrition Examination Survey evaluating the exposure to perchlorate, thiocyanate, and nitrate in 3151 participants aged 12 to 80.Blood serum free thyroxine (FT4) as both a continuous and categorical variable. We also assessed blood serum thyroid stimulating hormone.Controlling for serum cotinine, body mass index, total daily energy consumption, race/ethnicity, and poverty-to-income ratio, for each log unit increase in perchlorate, FT4 decreased by 0.03 ng/dL in both the general population (P = 0.004

Full Text available with Trip Pro

2017 Journal of Clinical Endocrinology and Metabolism

145. Central hypothyroidism due to a TRHR mutation causing impaired ligand affinity and transactivation of Gq. (PubMed)

; p.I131T) was identified in an 8-year-old boy with moderate hypothyroidism (TSH: 2.61 mIU/L, Normal: 0.27 to 4.2; free thyroxine: 9.52 pmol/L, Normal: 10.9 to 25.7) who was overweight (body mass index: 20.4 kg/m2, p91) but had normal stature (122 cm; -0.58 standard deviation). His mother, two brothers, and grandmother were heterozygous for the mutation with isolated hyperthyrotropinemia (TSH: 4.3 to 8 mIU/L). The I131T mutation, in TRHR intracellular loop 2, decreases TRH affinity and increases

Full Text available with Trip Pro

2017 Journal of Clinical Endocrinology and Metabolism

146. Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Brain Tumors From Melanoma and Glioblastoma

glioblastoma multiforme (GBM) receiving pembrolizumab with standard of care chemo-radiation. (Arm 2) SECONDARY OBJECTIVES: I. Determine the safety and toxicity of pembrolizumab when used in combination with standard of care stereotactic radiation (arm 1) and chemo radiation (arm 2). II. Determine the progression free survival (PFS), overall survival (OS), clinical response and duration of best response for each arm. TERTIARY OBJECTIVES: I. Compare the immune response as determined by the volume, pattern (...) . Investigate the feasibility of measuring vascular volume fraction (VVF), vessel size index (VSI) and vessel density index (VDI) as surrogate for response (true vs pseudoprogression, as determined by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 and immune related response criteria [irRC]). OUTLINE: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 2 years or 35 courses in the absence of disease progression or unacceptable

2017 Clinical Trials

147. Endocrinological Evaluations of a Neurofibromatosis Type 1 Cohort: Is it Necessary to Evaluate Autoimmune Thyroiditis in Neurofibromatosis Type 1? (PubMed)

neurofibromatosis type 1 and thyroid diseases.Case-control study.The study includes 78 consecutive patients diagnosed with neurofibromatosis type 1 between June 2010 and June 2014 and 50 healthy controls. Baseline demographic data were generated from patient examination record forms, including age, sex, height, and weight, as well as levels of free triiodothyronine, free thyroxine, thyroid-stimulating hormone, anti-thyroid peroxidase and anti-thyroglobulin levels.Mean age, sex, and body mass index were similar (...) in both groups (p>0.05). The mean levels of free triiodothyronine, free thyroxine, and thyroid-stimulating hormone were not statistically different between the neurofibromatosis type 1 and control groups. Similarly, no statistically significant difference was observed between the neurofibromatosis type 1 and control groups for anti-thyroid peroxidase and anti-thyroglobulin positivity (2.5% vs 0%, p>0.05).Screening for autoimmune thyroid disease and thyroid function seems to be unnecessary in patients

Full Text available with Trip Pro

2017 Balkan medical journal

148. Pericardial Effusion as a Presenting Symptom of Hashimoto Thyroiditis: A Case Report (PubMed)

cause of the pericardial fluid excess was considered unlikely. Thyroid function testing revealed very high thyrotropin (TSH, 487 μIU/mL; normal range, 0.340-5.600 μIU/mL) and low serum-free thyroxine (fT4, 0.04 ng/dL; normal range, 0.54-1.24 ng/dL) levels. High thyroid peroxidase antibody titres in the blood were evidenced (>1500 UI/L; normal values, 0.0-9.0 UI/L). The thyroid ultrasound was consistent with thyroiditis. HT was diagnosed, and LT4 replacement therapy with levothyroxine sodium 1.78 µg (...) of HT is described. Case presentation: A four-year-old male child suffering for a few months from recurrent abdominal pain sometimes associated with vomiting underwent an abdominal ultrasound scan outside the hospital. This led to the identification of a significant pericardial effusion. At admission, his family history revealed that both his mother and maternal grandmother suffered from HT and that both were treated with l-thyroxine (LT4). The clinical examination did not reveal any pathological

Full Text available with Trip Pro

2017 International journal of environmental research and public health

149. Levothyroxine for Non-Alcoholic Fatty Liver Disease (NAFLD)

, hyper/hypothyroidism, anxiety disorder, Graves' disease, thyroid/liver surgery, lactose intolerance, or malabsorption Baseline estimated glomerular filtration rate (eGFR) < 60 ml/min Currently on or within 6 months from the time of screening on either thyroxine, thiazolidinedione (TZD), oral T4/T3, anticoagulants (coumadin and warfarin), anti-viral drugs such as the protease inhibitors (ritonavir, indinavir, lopinavir), phenytoin, colestyramine, aluminium containing drugs (antacids, sucralfate (...) Baseline free T4 of more than the institution's specified reference range If a sole blood test result is deemed borderline according to the laboratory reference interval and not clinically significant, the investigator is authorized to exercise discretion. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study

2017 Clinical Trials

150. A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers

bilirubin; at screening alone - free thyroxine and thyroid-stimulating hormone) as a criteria of safety and tolerability variables. A reduced safety laboratory screen will be done at Day -1 or pre-dose at Day 1 and at 48 hours post-dose for all treatment periods. Laboratory assessments of urinalysis [ Time Frame: At screening (28 days prior to Day 1 of treatment period 1), treatment periods (At pre-dose on Day -1 to Day 3 (48 hours post-dose) and follow-up (14 days after discharge from the treatment (...) Healthy Volunteers: Yes Criteria Inclusion Criteria: Participants must fulfill the following criteria: Provision of signed and dated, written informed consent prior to any study specific procedure. Healthy vasectomized male participants with suitable veins for cannulation or repeated venipuncture, non-Japanese vasectomized male participants aged 18 to 55 years (inclusive) or male participants over 40 (and up to 55) years old not intending to father children. Body mass index (BMI) between 18 and 30 kg

2017 Clinical Trials

151. Establishing Global Reference Values for Human Milk

delivery. Other data collected on mothers and infants, including maternal and infant nutrient intake and status, morbidity, milk volume, and infant development, will inform interpretation and support application of the results. While the priority is to develop RVs for MN, other analyses will include human milk oligosaccharides (HMOs) and proteins, and free amino acids (FAA) in infant plasma. Thus, with the samples obtained the investigators will perform (a) laboratory analyses of milk, plasma and urine (...) and infants will be assessed in blood and urine Milk volume [ Time Frame: 1-3.4, 3.5-5.9, and 6-8.5 months postpartum ] Measurements of usual daily milk volume using deuterated water or, in Denmark, 24 hour infant weighing Maternal and infant iodine status [ Time Frame: 1-3.4, 3.5-5.9, and 6-8.5 months postpartum ] Urinary iodine; thyroid stimulating hormone, thyroglobulin and thyroxine in dried blood spots Milk iodine [ Time Frame: 1-3.4, 3.5-5.9, and 6-8.5 months postpartum ] Milk iodine Maternal

2017 Clinical Trials

152. Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases

resonance imaging (MRI) with ferumoxytol in predicting true vs pseudoprogression after stereotactic radiosurgery (SRS) and intravenous (IV) pembrolizumab in subjects with brain metastases from non-small cell lung cancer (NSCLC). SECONDARY OBJECTIVES: I. Evaluate the safety and tolerability of pembrolizumab when given with SRS in subjects with brain metastasis. II. Evaluate progression free survival, overall survival, best response in brain disease, best response in systemic disease, and duration of best (...) tissue before and after therapy at the time of progression. IV. In subjects with measurable systemic lesions, investigate the feasibility of measuring vascular volume fraction (VVF), vessel size index (VSI) and vessel density index (VDI) as surrogate for response (true vs. pseudoprogression, as measured with Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria). OUTLINE: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Courses repeat every 3 weeks for up to 2

2017 Clinical Trials

153. Pembrolizumab in Elderly Patients With Advanced Lung Cancer

Criteria (irRC). However, for determination of overall response rate (ORR) and progression-free survival (PFS), the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 will be used. Adverse events will be monitored throughout the trial and graded in severity according to the guidelines outlined in the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Treatment with MK-3475 will continue until two years of therapy have been administered, documented disease progression (...) cancer. Impact on functional assessments measured with Barthel scale [ Time Frame: From the first dose until the last dose of treatment (12 months later) ] To evaluate the impact on functional geriatric assessments of patients older than 70 years with advanced non-small cell lung cancer. Progression-free Survival (PFS) [ Time Frame: From the inclusion date in the study until first progression (at 9 months approximately) documented according to RECIST criteria ] To describe Progression-free Survival

2017 Clinical Trials

154. Interaction Between Levothyroxine and Probiotics in Hypothyroid Patients

completion, an average of 4 months ] measurement of serum levels of free triiodothyronine (fT3) - unit of measure: pg/mL, normal range: 1.7-3.7; measurement of serum levels of free thyroxine (fT4) - unit of measure: pg/mL, normal range: 7-15 Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you (...) , the following data were collected: probiotic assumption, sex, age, hypothyroidism aetiology, LT4 formulation dose and brand, body mass index (BMI), body surface area (BSA), systolic blood pressure, diastolic blood pressure, heart rate, TSH, fT4, fT3 and any possible LT4 posology adjustment. All the clinical data have been further databased. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 80 participants Allocation: Randomized

2017 Clinical Trials

155. A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis Patients

this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Prevalent hemodialysis patients, elevated thyrotropin level, normal free thyroxine level. Exclusion Criteria: Hyperthyroidism, active treatment with thyroid hormone replacement, prior (...) : Baseline and 12 weeks ] Change in serum soluble CD40 ligand level Body mass index [ Time Frame: Baseline and 12 weeks ] Change in body mass index Biceps skinfold [ Time Frame: Baseline and 12 weeks ] Change in biceps skinfold Triceps skinfold [ Time Frame: Baseline and 12 weeks ] Change in triceps skinfold Mid-arm circumference [ Time Frame: Baseline and 12 weeks ] Change in mid-arm circumference Mid-arm muscle circumference [ Time Frame: Baseline and 12 weeks ] Change in mid-arm muscle circumference

2017 Clinical Trials

156. A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)

retardation, or any other disease/procedure/accident/intervention which, according to the screening clinician, is deemed associated with significant injury to or malfunction of the CNS, or history of significant head trauma within the past 2 years. Presents with any of the following lab abnormalities: Thyroid stimulating hormone (TSH) outside of the normal limits and clinically significant as determined by the investigator. Free thyroxine (T4) levels may be measured if TSH level is high. Subject (...) one of the following methods of birth control during the course of the study, defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly: implants, injectable or patch hormonal contraception, oral contraceptives, IUD, double-barrier contraception, sexual abstinence. The form of birth control will be documented at screening and baseline. Body mass index between 18-35 kg/m2. Concurrent psychotherapy will be allowed if the type (e.g

2017 Clinical Trials

157. Factors Associated with the Prevalence of Thyroid Nodules and Goiter in Middle-Aged Euthyroid Subjects (PubMed)

Cohort study. Thyroid-stimulating hormone (TSH), free thyroxine (FT4), and antithyroid peroxidase antibody (ATPO) levels, as well as anthropometric and metabolic parameters and smoking information, were evaluated. Results. In subjects with and without thyroid nodules, thyroid volume correlated with components of metabolic syndrome, body mass index (BMI), smoking, and TSH levels. In the nonnodular thyroid group, thyroid volume was also positively related to serum insulin and HOMA-IR, whereas

Full Text available with Trip Pro

2017 International journal of endocrinology

158. Thyroid function/antibodies in sudanese women with polycystic ovarian disease (PubMed)

(thyroid-stimulating hormone, free tri-iodothyronine, and free thyroxine), anti-thyroid peroxidase, and anti-thyroglobulin antibodies were measured.While there were no significant differences in the age and haemoglobin levels of the two studied groups (55 women in each arm), body mass index was significantly higher in women with PCOS. There were no significant differences in the levels of thyroid-stimulating hormone, luteinizing hormone, follicle stimulating hormone, luteinizing hormone/follicle (...) stimulating hormone, anti-thyroid peroxidase, anti-thyroglobulin antibodies, cholesterol, triglycerides and low-density lipoprotein cholesterol between the cases and the controls. The mean±standard deviation of free tri-iodothyronine (3.50±0.2 vs. 3.38±0.3 pg/mL, P=0.040) and median (interquartile) high-density lipoprotein cholesterol (37.0 [34.0 to 42.0] vs. 35.80 [29.0 to 41.0] mg/dL, P=0.015) were significantly higher in PCOS patients compared with the control group. In linear regression, PCOS (0.151

Full Text available with Trip Pro

2017 Obstetrics & gynecology science

159. Subclinical Hypothyroidism in Danish Lean and Obese Children and Adolescents (PubMed)

Childhood Obesity Biobank. The overweight/obese group (n=1796) consisted of study participants with a body mass index (BMI) standard deviation score (SDS) ≥1.28. The control group (n=1210) comprised lean children with a BMI SDS <1.28. All participants were characterized by anthropometrics (weight, height, and waist circumference) and fasting serum concentrations of thyroid-stimulating hormone (TSH), free triiodothyronine, and free thyroxine (fT4) at baseline.The prevalence of SH was higher among

Full Text available with Trip Pro

2017 Journal of clinical research in pediatric endocrinology

160. Frequency of nodular goiter and autoimmune thyroid disease and association of these disorders with insulin resistance in polycystic ovary syndrome (PubMed)

factors affect these thyroid disorders.Ninety-seven women with PCOS and 71 healthy female volunteers were recruited into the study. Serum-free thyroxine, thyroid-stimulating hormone, anti-thyroperoxidase antibody and anti-thyroglobulin antibody levels were evaluated. Thyroid volume (TV) was calculated using ultrasonography.The body mass index (BMI), Waist/Hip ratio, homeostasis model assessment insulin resistance (HOMA-IR), fasting blood glucose, triglyceride and low-density lipoproteins, and fasting

Full Text available with Trip Pro

2017 Journal of the Turkish German Gynecological Association

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>